Are Peptides Legal? FDA Status and Compounding Rules

Knowledge

Nov 6, 2026

Portrait Care Team

The Portrait Team

ON THIS PAGE

Empowering Professionals at Every Stage

Portrait offers strategic expertise to help you make informed decisions and achieve long-term success.

Book Intro Call

Last reviewed November 6, 2026 by The Portrait Team.

This page provides regulatory education, not legal or medical advice; rules change, so check with your state boards and your own attorney before acting.

Are peptides legal? Your practice needs a product-specific answer. For owners, medical directors and clinical teams, the useful starting point is a clear distinction between approval, compounding status and a research-only label. This guide explains what to verify before discussing a product with patients.

Are peptides legal for med spas?

It depends on the exact product. Verify its FDA approval record and any applicable section 503A or 503B conditions. A research-use-only label does not establish permission for patient use.

These categories answer different questions. FDA approval concerns an approved drug product. Compounding operates under a separate framework. FDA says compounded drugs should only be used when an FDA-approved drug cannot meet a patient's medical needs.

A research-only statement does not establish permission for patient use. FDA's warning letter shows that labeling and website evidence can establish intended human drug use despite that statement. For your practice, the label alone is not a sufficient regulatory answer.

How do approval, compounding, research-only labeling and cosmetics differ?

FDA approval, compounding requirements and research-only labeling answer different regulatory questions. Cosmetic ingredients belong to a separate category defined by intended use.

Under FDA's section 503A pharmacy guidance (opens in a new tab), a compounded drug must be for an identified individual patient based on a valid prescription order. A 503B outsourcing facility has FDA oversight and current good manufacturing practice requirements. Neither type of compounded drug receives FDA approval before marketing.

The FDA cosmetic and drug distinction (opens in a new tab) turns on intended use. Cosmetic products and ingredients generally need no FDA premarket approval, with an exception for color additives. That is a different regulatory framework from drug approval or compounding.

The table compares regulatory categories and oversight, checked November 6, 2026.
What it is	FDA review before sale	Who oversees it	What it means for a practice
FDA-approved peptide drug	FDA-approved product	FDA approval framework	Verify the exact approved product.
Compounded drug, 503A pharmacy or physician	No FDA approval or premarket safety, effectiveness or quality review	State pharmacy boards oversee state-licensed pharmacies day to day	Verify an identified patient's valid prescription and applicable 503A conditions.
Compounded drug, 503B outsourcing facility	No FDA approval or premarket safety, effectiveness or quality review	FDA oversight and inspection; current good manufacturing practice requirements	FDA oversight does not make the compounded drug FDA-approved.
Research-use-only product	A research-only label does not establish FDA approval	FDA evaluates evidence of intended human drug use	Do not treat research-only labeling as permission for patient use.
Cosmetic peptide ingredient	Generally no premarket approval; color additives are an exception	FDA cosmetic framework	Verify that intended use and claims fit the cosmetic category.

For the distinction between compounders, see 503A and 503B pharmacy differences. When assessing compounded peptides or a peptide compounding pharmacy, separate oversight of the compounder from approval of the finished drug.

Which peptides are FDA-approved?

The approval records covered here include Vyleesi (bremelanotide) and Egrifta (tesamorelin); the two GEREF applications for sermorelin are discontinued.

The Drugs@FDA record for Vyleesi (opens in a new tab) lists application NDA 210557, original approval on June 21, 2019, and prescription marketing status. The Drugs@FDA record for Egrifta (opens in a new tab) lists original approval on November 10, 2010, and prescription marketing status under BLA 022505. Drugs@FDA lists Egrifta as a BLA because its former NDA was deemed a BLA on March 23, 2020.

The Drugs@FDA records for GEREF application NDA 019863 (opens in a new tab) and GEREF application NDA 020443 (opens in a new tab) list both as discontinued. FDA withdrew approval of both GEREF applications (opens in a new tab) effective June 18, 2009.

A Drugs@FDA search on November 4, 2026 returned no application listing BPC-157, thymosin (TB-500), MOTS-c, CJC-1295, ipamorelin, kisspeptin, AOD-9604 or GHK-Cu as an active ingredient.

For FDA-approved peptides, verify the product and application record rather than relying on the ingredient name alone. Egrifta's BLA classification also matters: biological products are not eligible for the compounding exemptions under sections 503A and 503B.

What do the 503A bulks list and category 2 peptides mean?

The 503A bulks list is one qualifying path for bulk drug substances; category 2 identifies substances for which FDA has found significant safety risks.

FDA's 503A bulk substance framework (opens in a new tab) sets out three paths. A bulk substance must meet an applicable USP or NF monograph and the USP pharmacy compounding chapter. If no applicable monograph exists, it must be a component of an FDA-approved drug. If neither applies, it must appear on the 503A bulks list. Bulk substances also need a valid certificate of analysis and must be manufactured by an FDA-registered establishment.

The interim categories have distinct meanings:

Category 1: substances nominated with enough supporting information for evaluation. FDA does not intend to take action under the category 1 policy when its guidance conditions are met.
Category 2: substances with significant safety risks identified by FDA. FDA would consider enforcement against compounding with them under its general enforcement policies.
Category 3: substances nominated without enough supporting information. They are outside the category 1 policy.

Category placement is not the same as inclusion on the bulks list. FDA does not intend to place substances nominated on or after January 7, 2025 into these categories. Your practice should also verify the patient-specific prescription requirement and the restriction against regularly, or in inordinate amounts, compounding essentially copies of commercially available drugs. A category entry alone does not answer those questions.

What changed for peptides in 2026?

The record changed through nomination withdrawals, category updates, advisory committee review and an HHS draft enforcement policy, without making the six policy-listed peptides FDA-approved.

On April 22, 2026, FDA's withdrawn nomination record (opens in a new tab) listed BPC-157, TB-500, MOTS-c and other substances as previously in category 2 after their nominators withdrew them. The HHS policy appendices and conditions (opens in a new tab) expressly state that neither placement in nor removal from category 2 changed BPC-157's status under section 503A.

The FDA category lists, May 14, 2026 (opens in a new tab) contain six category 2 entries, including kisspeptin-10. FDA lists separate GHK-Cu entries with different category records. FDA intends to consult its Pharmacy Compounding Advisory Committee about GHK-Cu before the end of February 2027.

At the July 2026 advisory committee meeting (opens in a new tab), held on July 23 and July 24, 2026, the committee discussed BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon. The FDA briefing on seven peptides (opens in a new tab) proposed against listing all seven. HHS records favorable committee votes for six: BPC-157, TB-500, epitalon, semax, KPV and MOTS-c. Committee recommendations are non-binding. On October 30, 2026, HHS published notice of its draft enforcement discretion policy. That draft is a separate development from FDA approval or a final bulks-list rule.

FDA status of peptides practices ask about, checked November 6, 2026.
Peptide	FDA-approved product?	503A category status	In the HHS draft policy (October 30, 2026)?
BPC-157	No	Nomination withdrawn; out of category 2 since April 22, 2026	Yes (Appendix A)
TB-500	No	Nomination withdrawn; out of category 2 since April 22, 2026	Yes
MOTS-c	No	Nomination withdrawn; out of category 2 since April 22, 2026	Yes
KPV, semax, epitalon	No	Nominations withdrawn; out of category 2 since April 22, 2026	Yes
CJC-1295	No	Nomination withdrawn; out of category 2; FDA notes serious adverse events	No
Ipamorelin	No	503A nomination withdrawn; in 503B category 2 since September 29, 2023	No
GHK-Cu	No approved drug	Separate FDA entries with different records; verify the current entry	No
Kisspeptin-10	No	Category 2 since September 29, 2023	No
AOD-9604	No	Nomination withdrawn; out of category 2	No
Sermorelin	No; GEREF approvals withdrawn effective June 18, 2009	Not on FDA's 503A category lists (May 14, 2026)	No
Bremelanotide (PT-141)	Yes, Vyleesi (2019)	Verify the bulk-substance pathway and all other 503A conditions	No
Tesamorelin	Yes, Egrifta (2010), a BLA	Biological products are not eligible for the 503A and 503B compounding exemptions	No

What does the HHS draft policy allow, and what does it not?

The draft states an intent not to take enforcement action against specified compounders meeting its conditions; it does not make any of the six listed peptides FDA-approved.

Its stated scope covers a state-licensed pharmacy, federal facility or licensed physician compounding with a peptide in Appendix A. The listed conditions include:

Compliance with the identity and administration limitations in Appendix B.
An active pharmaceutical ingredient from an FDA-registered facility, characterized and identified in a valid certificate of analysis.
Reporting products compounded, serious adverse events and quality issues to FDA and the relevant states.
The label statement: “This is a compounded drug product. Not for resale.”
A single active pharmaceutical ingredient listed in Appendix A.
An FDA 510(k)-cleared syringe as the only delivery device co-packaged with or containing the compounded drug.
Compliance with section 503A's patient-specific prescription requirement.

The draft creates no rights and is not binding on HHS or the public. HHS may revisit it if a safety signal or product quality issue arises. The notice permits comments for two weeks after publication under Docket No. HHS-OASH-2026-0496. Future FDA rulemaking may propose adding some or all of the peptides to the bulks list; that possibility is not a completed listing decision.

HHS states that the policy aims to discourage widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients. That stated aim does not change the approval status of compounded drugs.

Are research-use-only peptides legal to use on patients?

A research-use-only label does not establish that a peptide is legally available for patient use.

In its June 17, 2026 warning letter, FDA said research-only and not-for-human-consumption statements did not prevent it from finding that the products were intended as drugs for human use. FDA relied on evidence from product labeling, including the website.

For your practice, the distinction is between a disclaimer and the evidence of intended use. HHS's stated concern about research-only peptides also explains the aim of its limited enforcement policy. Neither the disclaimer nor that policy's stated aim is proof of FDA approval.

Where do cosmetic peptides fit?

Topical skincare falls within the cosmetic category when its intended use and claims are cosmetic.

Claims help determine the regulatory category. Cosmetic products and ingredients generally do not require FDA approval before marketing, except for color additives. Keep that cosmetic framework separate from a discussion of approved or compounded drugs.

What should a practice verify before discussing any peptide with patients?

Verify the exact product record, applicable compounding requirements, oversight, claims and current policy date before presenting a regulatory conclusion.

Use these questions to organize the review:

Product record: Is there an FDA approval for the exact product? Does the application show prescription or discontinued status? Keep the application record with your review.
Compounding basis: If section 503A applies, which bulk-substance path supports it? Verify the identified patient's valid prescription requirement separately from category status.
Oversight: Is the compounder a state-licensed pharmacy with day-to-day state board oversight, or a 503B outsourcing facility overseen and inspected by FDA?
Promotion and evidence: Prescription drug promotion by or for manufacturers, including compounders, must be truthful, non-misleading and accurate. FTC guidance on health claims (opens in a new tab) requires competent and reliable scientific evidence for health benefit or safety claims.
Date and jurisdiction: Recheck the category lists and HHS policy. Category placement has a nomination-date cutoff, and HHS may revisit its policy. Use the state laws guide below with your own attorney and state boards.

For anyone asking “are peptides legal in the US,” this review keeps the answer tied to a specific product and current record. Document what you verified and what still needs an answer before using a broad statement such as “legal” in patient-facing copy.